Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.
While the tests will likely help drug companies like Eli Lilly and Co. evaluate medicines, they’ll also create wrenching personal and ethical dilemmas for patients who will have to live with the knowledge that they’re destined to develop the disease.
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
A major drugmaker that was part of three-way multi-billion-dollar deal this year involving Eli Lilly and Co. is planning a reorganization that will include hundreds of job cuts in the United States.
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.
That’s a 9-percent reduction from the government’s May estimate of 8 million, which reflected only how many people had signed up, not how many had paid and were enrolled in the coverage.
The agency on Thursday cleared the drug, Trulicity, as a weekly injection to improve blood sugar control in patients with type 2 diabetes, which affects more than 26 million Americans.
Drugmakers, including Eli Lilly and Co., should conduct new trials to assess the heart risks of testosterone therapies used by millions of men last year, advisers to U.S. regulators said.
Testosterone supplements used last year by about 2.3 million men are spurring debates over how necessary and safe they may be, even as U.S. regulators consider approving a new product.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
Eli Lilly and Co. said Friday its potential colorectal cancer drug Cyramza helped patients on chemotherapy with advanced cases of the disease survive longer than patients on chemotherapy alone.
European regulators have approved a long-lasting insulin from Eli Lilly and Co. and German drugmaker Boehringer Ingelheim that is the subject of patent-infringement litigation with French rival Sanofi.
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Takeda Pharmaceutical Co. and Eli Lilly and Co. lost a bid to have a judge throw out a combined $9 billion punitive-damage award over claims the drugmakers hid the cancer risks of their Actos diabetes medicine.
A Carmel-based institutional pharmacy plans to invest $8 million expanding its Noblesville operations, which include its headquarters. On Tuesday, it received its second tax-incentive deal from the city in two years.
